- The Technology››
- Healthcare associated infections››
- About Bactiguard››
Bactiguard – a history of innovation
Bactiguard was founded in 2005, but the technology is almost a hundred years old
It stems from the Swedish Nobel Prize laureate in in physics 1912, Gustav Dahlén, the man behind the famous AGA Lighthouse. Gustav Dahlén had an apprentice called Axel Bergström, who developed the technique of applying a thin layer of metals to non-conductive materials. Axel then passed this knowledge on to his apprentice, Billy Södervall.
Applying for patents in USA
Billy Södervall, the innovator behind the Bactiguard technology, refined the technique and in the 1970’s, he started applying the coating of noble metals to medical devices. The results proved very effective and led him to applying for patents in the USA.
The company entered into a partnership with US medical device company C.R. Bard (later acquired by BD). In 1994, the US Food and Drug Administration (FDA) approved the Bardex IC Foley catheters, Bard’s urinary catheters with the Bactiguard infection preventive coating. The catheters were launched on the US market the following year and are market leading in the US and Japan.
Bactiguard AB was founded in Sweden in 2005 and acquired the business and technology from the previous owner. The ambition was to take the technology a step further by developing a proprietary portfolio of infection preventive products for hospital care. In 2006, a development and production unit was established in Markaryd, in the south of Sweden, to focus on the further development of the technology.
Launch of BIP portfolio
In 2006, work started on developing a proprietary product portfolio and in 2008 the first Bactiguard Infection Protection, BIP Foley catheters in latex were launched. BIP Foley Silicone reached the market the following year.
In 2013, Bactiguard coated central venous catheters (BIP CVC) and endotracheal tubes (BIP ETT) were launched. A production unit was established the same year in Malaysia, to manufacture urinary catheters.
Stock exchange listing
In June 2014, Bactiguard was floated on the stock exchange through an IPO, with the purpose of refinancing the company and enabling market expansion. The shares are listed and traded on the NASDAQ Stockholm under the stock symbol Bacti.
New integrated headquarters
In late 2014, Bactiguard relocated its headquarters to a new facility located at Alfred Nobels Allé in Tullinge, south of Stockholm. The new office enabled all parts of the company such as sales and marketing, staff functions, product development and production to come together under the same roof. Another advantage of being based in the Karolinska Institute Science Park is proximity to research and development at the Karolinska Institute and the Royal Institute of Technology, as well as healthcare professionals at Karolinska University Hospital which facilitates closer cooperation.
Expanding the BIP portfolio
In 2016, BIP ETT Evac is launched. Two years later the BIP Foley catheter range was extended by two new variants; Female and Tiemann. At the same time, the BIP CVC range was expanded by a safer and more user friendly, with a Raulserson syringe. The product portfolio and market presence are continuously expanded and Bactiguard now operates in some 40 countries and the technology is available on all continents.